San Francisco, CA, USA, June 1 2017 – Trianni, Inc. (“TRIANNI”) announced today that it has entered into an agreement […]
TRIANNI and Olympic Protein Technologies Sign License Agreement for The Trianni Mouse™
San Francisco, CA and Seattle, WA, USA., May 24, 2017 –Trianni, Inc. (“TRIANNI”) and Olympic Protein Technologies (“Olympic”) jointly announced […]
Immunomic Therapeutics and TRIANNI Sign License Agreement for The Trianni Mouse™
Rockville, MD and San Francisco, CA, USA, May 18, 2017–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, and […]
TRIANNI Signs Agreement with Magenta Therapeutics for Use of The Trianni Mouse
San Francisco, CA, USA., March 22, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement […]
TRIANNI Signs Collaboration Agreement with Fred Hutchinson Cancer Research Center for use of The Trianni Mouse Platform
San Francisco, CA, USA, March 8, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has finalized a non-exclusive license agreement […]
GigaGen and Trianni Announce License Agreement for Discovery of Fully Human Immuno-Oncology Antibodies
Partnership leverages GigaGen’s industry-leading immune repertoire sequencing and expression technology and Trianni’s best-in-class human transgenic mouse platform. February 28, 2017– […]
TRIANNI Signs Agreement with Stanford University for Use of The Trianni Mouse in Vaccine Research
San Francisco, CA, USA., February 22, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement […]
TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen
San Francisco, CA, USA., February 15, 2017 –Trianni, Inc. (“TRIANNI”) announced today that it has entered into a license agreement […]
TRIANNI is BioWorld’s Partner in Focus
TRIANNI is featured in BioWorld Today as a Partner in Focus. Read the feature here. The feature highlights: • Advantages […]
Transgenic Mice: Transforming Targeted Monoclonal Antibody (mAb) Therapeutics
Download Full Whitepaper Monoclonal antibodies (mAbs) currently represent the largest class of biopharmaceutical products. Market growth is projected to climb […]
Recent Comments